Health Care [ 4/12 ] | Biotechnology [ 18/73 ]
NASDAQ | Common Stock
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
It has a research collaboration agreement with CRISPR Therapeutics AG.
Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 25 | -0.29 Increased by +25.64% | -0.34 Increased by +14.20% |
| Aug 12, 25 | -0.31 Increased by +8.82% | -0.35 Increased by +11.43% |
| May 7, 25 | -0.43 Increased by +25.86% | -0.45 Increased by +4.44% |
| Mar 19, 25 | -0.35 Increased by +38.60% | -0.40 Increased by +12.50% |
| Nov 7, 24 | -0.39 Increased by +25.00% | -0.36 Decreased by -8.33% |
| Aug 13, 24 | -0.34 Increased by +43.33% | -0.45 Increased by +24.44% |
| May 9, 24 | -0.58 Increased by +7.94% | -0.56 Decreased by -3.57% |
| Mar 21, 24 | -0.57 Increased by +14.93% | -0.59 Increased by +3.39% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -21.71 M Increased by +23.39% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -22.98 M Increased by +8.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -31.98 M Decreased by -8.35% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 9.03 M Decreased by -14.30% | -25.93 M Increased by +6.55% | Decreased by -287.08% Decreased by -9.04% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -28.34 M Decreased by -10.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -24.99 M Increased by +24.92% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -29.52 M Increased by +4.21% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 10.54 M Increased by +N/A% | -27.75 M Increased by +14.82% | Decreased by -263.27% Decreased by N/A% |